CD8A and neoplasm: Furthermore, an enhanced antitumor immunological response contributed to preventing tumor recurrence, i.e., Rh2, when used as an adjuvant, was found to trigger CD4+/CD8a+ T-lymphocyte infiltration in tumor tissues and to increase T-lymphocyte cytotoxicity with cancer chemotherapeutic drugs [42].